Zynex (ZYXI) Stock Price
Zynex Price
Over the last 19 years Zynex grew revenue by 26.4% annually, reaching 192.35 M USD. Earnings per share have grown at 17.1% per year over the last 19 years. For Zynex, the net margin of 1.6% is down versus 11.3% a few years ago. At today's price the dividend yield works out to roughly 0.80%. The payout ratio is around 0% of earnings. The dividend has grown at 9.3% per year over the past 4 years. The consensus 12-month price target for Zynex is 3.77 USD, about 2,919.2% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Zynex stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Zynex over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Zynex stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Zynex's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Zynex Price |
|---|---|
| 12/23/2025 | 0.13 USD |
| 12/22/2025 | 0.19 USD |
| 12/19/2025 | 0.29 USD |
| 12/18/2025 | 0.28 USD |
| 12/17/2025 | 0.26 USD |
| 12/16/2025 | 0.34 USD |
| 12/15/2025 | 0.34 USD |
| 12/12/2025 | 0.38 USD |
| 12/11/2025 | 0.44 USD |
| 12/10/2025 | 0.45 USD |
| 12/9/2025 | 0.44 USD |
| 12/8/2025 | 0.42 USD |
| 12/5/2025 | 0.46 USD |
| 12/4/2025 | 0.53 USD |
| 12/3/2025 | 0.60 USD |
| 12/2/2025 | 0.60 USD |
| 12/1/2025 | 0.63 USD |
| 11/28/2025 | 0.65 USD |
| 11/26/2025 | 0.82 USD |
| 11/25/2025 | 0.38 USD |
| 11/24/2025 | 0.38 USD |
| 11/21/2025 | 0.32 USD |
| 11/20/2025 | 0.25 USD |
| 11/19/2025 | 0.29 USD |
| 11/18/2025 | 0.22 USD |
| 11/17/2025 | 0.29 USD |
| 11/14/2025 | 0.29 USD |
| 11/13/2025 | 0.40 USD |
| 11/12/2025 | 0.57 USD |
| 11/11/2025 | 0.60 USD |
| 11/10/2025 | 0.61 USD |
| 11/7/2025 | 0.53 USD |
| 11/6/2025 | 0.54 USD |
| 11/5/2025 | 0.58 USD |
| 11/4/2025 | 0.59 USD |
| 11/3/2025 | 0.60 USD |
| 10/31/2025 | 0.59 USD |
| 10/30/2025 | 0.64 USD |
| 10/29/2025 | 0.68 USD |
| 10/28/2025 | 0.68 USD |
| 10/27/2025 | 0.70 USD |
| 10/24/2025 | 0.72 USD |
| 10/23/2025 | 0.70 USD |
| 10/22/2025 | 0.69 USD |
| 10/21/2025 | 0.73 USD |
| 10/20/2025 | 0.70 USD |
| 10/17/2025 | 0.68 USD |
| 10/16/2025 | 0.69 USD |
| 10/15/2025 | 0.71 USD |
| 10/14/2025 | 0.71 USD |
| 10/13/2025 | 0.71 USD |
| 10/10/2025 | 0.71 USD |
| 10/9/2025 | 0.74 USD |
| 10/8/2025 | 0.76 USD |
| 10/7/2025 | 0.75 USD |
| 10/6/2025 | 0.76 USD |
| 10/3/2025 | 0.76 USD |
| 10/2/2025 | 0.75 USD |
| 10/1/2025 | 0.74 USD |
| 9/30/2025 | 0.75 USD |
| 9/29/2025 | 0.76 USD |
| 9/26/2025 | 0.75 USD |
| 9/25/2025 | 0.76 USD |
| 9/24/2025 | 0.77 USD |
| 9/23/2025 | 0.79 USD |
| 9/22/2025 | 0.81 USD |
| 9/19/2025 | 0.80 USD |
| 9/18/2025 | 0.80 USD |
| 9/17/2025 | 0.77 USD |
| 9/16/2025 | 0.80 USD |
| 9/15/2025 | 0.76 USD |
| 9/12/2025 | 0.76 USD |
| 9/11/2025 | 0.79 USD |
| 9/10/2025 | 0.75 USD |
| 9/9/2025 | 0.77 USD |
| 9/8/2025 | 0.75 USD |
| 9/5/2025 | 0.77 USD |
| 9/4/2025 | 0.77 USD |
| 9/3/2025 | 0.77 USD |
| 9/2/2025 | 0.80 USD |
| 8/29/2025 | 0.84 USD |
| 8/28/2025 | 0.84 USD |
| 8/27/2025 | 0.86 USD |
| 8/26/2025 | 0.85 USD |
Zynex Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Zynex Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 11.00 | 13.00 | 23.00 | 31.00 | 45.00 | 80.00 | 130.00 | 158.00 | 184.00 | 192.00 | 91.00 | 101.00 | 111.00 | 121.00 | 133.00 |
| -47.62 | – | 18.18 | 76.92 | 34.78 | 45.16 | 77.78 | 62.50 | 21.54 | 16.46 | 4.35 | -52.60 | 10.99 | 9.90 | 9.01 | 9.92 |
| 27.27 | 54.55 | 69.23 | 78.26 | 80.65 | 80.00 | 77.50 | 78.46 | 79.75 | 78.80 | 79.17 | 79.17 | 79.17 | 79.17 | 79.17 | 79.17 |
| 3.00 | 6.00 | 9.00 | 18.00 | 25.00 | 36.00 | 62.00 | 102.00 | 126.00 | 145.00 | 152.00 | 72.04 | 79.96 | 87.88 | 95.79 | 105.29 |
| -5.00 | -2.00 | – | 8.00 | 10.00 | 11.00 | 10.00 | 22.00 | 22.00 | 11.00 | 5.00 | 10.00 | 11.00 | 12.00 | 13.00 | 14.00 |
| -45.45 | -18.18 | – | 34.78 | 32.26 | 24.44 | 12.50 | 16.92 | 13.92 | 5.98 | 2.60 | 10.99 | 10.89 | 10.81 | 10.74 | 10.53 |
| -6.00 | -2.00 | – | 7.00 | 9.00 | 9.00 | 9.00 | 17.00 | 17.00 | 9.00 | 2.00 | -41.00 | -14.00 | -11.00 | -8.00 | -3.00 |
| -14.29 | -66.67 | – | – | 28.57 | – | – | 88.89 | – | -47.06 | -77.78 | -2,150.00 | -65.85 | -21.43 | -27.27 | -62.50 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 34.40 | 34.40 | 32.05 | 37.86 | 37.02 | 37.51 | 39.19 | 39.36 | 37.96 | 34.01 | 32.30 | 32.30 | 32.30 | 32.30 | 32.30 | 32.30 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Zynex generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Zynex retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Zynex's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Zynex has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Zynex's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Zynex stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Zynex Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Zynex business model & stock analysis
Zynex SWOT Analysis
Strengths
Zynex Inc possesses a strong and experienced management team, which brings in-depth industry knowledge and expertise to the company. This enables them to make strategic decisions and navigate the competitive landscape effectively.
The company has a robust product portfolio that includes innovative medical devices, focusing on pain management and rehabilitation. This diversification allows Zynex Inc to cater to various customer needs and target multiple market segments.
Weaknesses
Zynex Inc heavily relies on a limited number of suppliers for its components and raw materials. Any disruption or issues in the supply chain could potentially impact their production and result in delayed deliveries.
The company's brand awareness and market penetration may be relatively lower compared to some of its larger competitors. This makes it challenging for Zynex Inc to capture a significant market share and compete effectively on a global scale.
Opportunities
The growing demand for pain management and rehabilitation devices presents a significant opportunity for Zynex Inc to expand its customer base and increase sales. The aging population and increasing prevalence of chronic diseases contribute to this favorable market trend.
Zynex Inc can explore strategic partnerships or collaborations with healthcare providers and institutions to enhance its distribution channels and gain access to a wider customer network. This would help increase brand visibility and drive sales growth.
Threats
Intense competition within the medical device industry poses a threat to Zynex Inc. Other established companies with greater resources and market presence may launch similar products or offer competitive pricing, potentially eroding Zynex Inc's market share.
Rapid technological advancements in the industry can also pose a threat as competitors may introduce more innovative and advanced products. Zynex Inc needs to stay ahead in terms of research and development to maintain a competitive edge.
Zynex Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Zynex Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Zynex historical P/E ratio, EBIT multiple, and P/S ratio
Zynex annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Zynex shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Zynex stock splits
Zynex Dividend History
3 years of dividend payments
Zynex dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Zynex forecasts and price targets in August 2026
Analyst Price Targets 2026Zynex Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/29/2026 | -0.11USD | - | 25.23 MUSD | - | 2026 Q2 |
| 4/27/2026 | -0.11USD | - | 26.47 MUSD | - | 2026 Q1 |
| 3/9/2026 | -0.11USD | - | 26.04 MUSD | - | 2025 Q4 |
| 11/17/2025 | -0.18USD | - | 23.48 MUSD | - | 2025 Q3 |
| 4/25/2024 | 0.04USD | - | 48.70 MUSD | - | 2024 Q1 |
| 3/4/2024 | 0.17USD | - | 55.62 MUSD | - | 2023 Q4 |
| 7/26/2023 | 0.12USD | - | 46.66 MUSD | - | 2023 Q2 |
| 4/26/2023 | 0.06USD | - | 39.88 MUSD | - | 2023 Q1 |
| 2/22/2023 | 0.20USD | - | 50.56 MUSD | - | 2022 Q4 |
| 10/27/2022 | 0.12USD | - | 42.05 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Zynex stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Zynex shareholder structure
| % | Name |
|---|---|
0.49358% | |
0.13541% | |
0.06910% | |
0.06757% | |
0.05611% | |
0.04482% |
Zynex Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
4.10% | SEC ↗ |
Zynex Executives and Management Board
9 members · avg. age 59 · 0 % women
Management
Mr. Steven Dyson (52)
Chairman of the Board, Chief Executive Officer · since 2025
Mr. Vikram Bajaj (49)
Chief Financial Officer, Treasurer
Mr. John Bibb (52)
Chief Legal Officer, Company Secretary
Mr. Quinn Callanan
IR Contact Officer · since 2024
Board of Directors
Mr. Barry Michaels (75)
Independent Director
Mr. Michael Cress (67)
Independent Director
Mr. Joshua Disbrow (50)
Independent Director
Mr. Paul Aronzon (70)
Independent Director
Mr. Bret Wise
Independent Director
Frequently asked questions about Zynex
Zynex Inc's business model revolves around developing, manufacturing, and marketing non-invasive medical devices and accessories. The company specializes in electrotherapy products that aid in pain management, rehabilitation, and physical therapy. Zynex Inc primarily focuses on three key business segments: electrotherapy, neurological diagnostics, and patient monitoring. With a commitment to innovation and quality, Zynex Inc serves healthcare professionals, patients, and medical institutions with its advanced medical technologies. Through this business model, Zynex Inc aims to improve patient outcomes, enhance quality of life, and contribute to the overall advancement of the medical industry.
Zynex Inc is primarily active in the medical device industry.
The main competitors of Zynex Inc in the market include companies such as Medtronic, Abbott Laboratories, and Neurometrix. These companies also specialize in medical devices and technology, providing similar products and services within the healthcare industry. Zynex Inc competes with these companies to capture market share and meet the needs of healthcare professionals and patients.
Zynex Inc is a reputable company with a rich history and background. Founded in 1996, Zynex has consistently grown and established itself as a leader in the medical technology industry. Specializing in electrotherapy devices, the company offers innovative solutions for pain management and rehabilitation. Zynex has successfully developed and commercialized numerous products that have helped improve the lives of patients worldwide. Their commitment to research and development, along with their dedication to customer satisfaction, has garnered them a strong reputation in the market. With a focus on technological advancements and a mission to enhance patient care, Zynex Inc continues to thrive and make a significant impact in the medical device industry.
Zynex Inc, a leading medical technology company, has achieved several significant milestones. The company successfully introduced NeuroMove, its flagship neuro rehabilitation therapy device, which has revolutionized the industry. Zynex Inc also received FDA approval for their innovative Pain Management products, including NexWave and Infinity Plus, providing advanced pain relief solutions to patients. Furthermore, the company expanded its reach across the United States, establishing a strong presence in the healthcare market. Zynex Inc's consistent focus on research and development, coupled with its commitment to improving patient outcomes, has positioned them as a leading player in the medical technology sector.
Zynex Inc is primarily present in the United States of America.
Zynex Inc represents values of innovation, excellence, and patient-centric care in the medical technology industry. With a corporate philosophy focused on delivering high-quality medical devices and exceptional customer service, Zynex Inc strives to enhance the lives of patients through advanced medical solutions. The company is dedicated to continuously innovating and developing state-of-the-art products that improve healthcare outcomes and patient experiences. Zynex Inc's commitment to excellence has made it a trusted name in the industry, providing effective and reliable medical solutions.
Analysts currently set an average price target of 3.77 USD for the Zynex stock (median: 3.77 USD), implying +2,919.2 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Zynex stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Zynex to generate revenue of 101.20 M USD and earnings per share of -0.45 USD.
Converted at the current exchange rate, the Zynex share trades at 0.11 EUR (0.13 USD).
The Zynex share (ZYXI) is listed on 1 stock exchanges, including: NASDAQ (ZYXI).
Zynex Inc is a healthcare company based in the United States that specializes in the development and marketing of medical devices and therapy equipment. The company was founded in 1996 and is headquartered in Lone Tree, Colorado. Zynex offers a wide range of products and services for various medical areas. The core areas of Zynex are electrotherapy, pain therapy, orthopedics, and neurology. In these areas, the company develops and produces medical devices such as electronic pain therapy devices, electromyography-guided therapy systems, neurological therapy devices, and custom-fit orthotic systems. Zynex's electrotherapy devices are used for pain relief and muscle stimulation. The devices are easy to use and can be used at home. The range includes portable muscle stimulation devices that relieve joint, back, or neck pain, as well as transcutaneous electrical nerve stimulation (TENS) devices that enable non-invasive pain treatment. Zynex also offers electromyography-guided therapy systems that are used in the rehabilitation after injuries or surgeries. These systems are specifically tailored to the individual needs of the patient and help restore muscle strength and function. In the field of neurology, Zynex offers devices for the treatment of stroke patients, including direct current stimulation systems and electronic muscle stimulation devices. These devices help improve the motor skills of the patients. Zynex's custom-fit orthotic system is an individually tailored orthosis system that provides protection and support for injuries or conditions. The orthotic systems are made from high-quality materials and are tailored to the individual needs of the patient. In addition to developing and manufacturing medical devices, Zynex also offers medical services, such as conducting electromyography tests and providing patients with orthotic aids. Zynex aims to offer medical products that improve patients' quality of life and contribute to their recovery. The company works closely with medical professionals to develop and launch its products on the market. In summary, Zynex Inc is an innovative and versatile company that specializes in the development and marketing of medical devices and therapy equipment. The company offers its customers a wide range of products and services that are tailored to the individual needs of patients. With its high-quality and effective products, Zynex contributes to people leading better and pain-free lives.
The expected revenue of Zynex is 101.20 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Zynex is -14.59 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Zynex is currently -0.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zynex stock.
The price-to-sales ratio (P/S) of Zynex is currently 0.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zynex stock.
The Eulerpool Quality Score for Zynex is 5/10.
The ISIN of Zynex is US98986M1036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Zynex is A0Q5XP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Zynex is ZYXI. The ticker symbol is used to trade Zynex shares on the stock exchange.
The current dividend yield of Zynex is 0.80 %.
Zynex paid dividends every year for the past 0 years.
Zynex is assigned to the 'Health' sector.
To receive the latest dividend of Zynex from amounting to 0.1 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Zynex are distributed in USD.
Zynex stock
Zynex Peer Group
Zynex Ticker
Zynex FIGI
All fundamentals and in-depth analysis of Zynex
Our stock analysis for Zynex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zynex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.